Ask AI
ProCE Banner Series

Optimizing Treatment of CLL/SLL: Expert Guidance on Application of the Latest Data

Interact with experts as they discuss the latest data on their approaches to caring for patients with CLL/SLL during a 1.5-hour live symposium, either in-person or online. Presenters will discuss recent advances and current best practices and strategies for pharmacists to improve patient adherence to therapy, mitigate treatment-related AEs, and communicate effectively with patients about their CLL/SLL care. Join us at 12:30-1:00 PM Pacific Time (PT) for in-person registration or at 1:00 PM PT online when the symposium beings. Register today!

  ACPE-P
Credits Available

1.5

Who Should Attend

The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with CLL/SLL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

All Events

Optimizing Treatment of CLL/SLL: Expert Guidance on Application of the Latest Data

Past Events

April

30

2023

1:00 PM - 2:30 PM Pacific Time (PT)

In-personVirtual

Asembia’s AXS23 Summit at Wynn Las Vegas, 3131 Las Vegas Blvd. S, Las Vegas, Nevada 89109

Topics

Welcome and Opening Remarks

Current Evidence and Best Practices in Treatment for CLL/SLL

Providing Collaborative, Evidence-Based, Equitable Oncology Care

Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, competence, and confidence of learners in the optimal treatment and associated therapies for CLL/SLL.

Target Audience
The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with CLL/SLL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply evidence, guidelines, and best practices to optimally integrate targeted drug classes in treatment-naive or relapsed/refractory CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens
  • Compare the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL
  • Evaluate the role of measurable residual disease, novel combinations, and CAR T-cell therapy in CLL/SLL
  • Manage adverse events associated with the use of targeted agents, including single-agent and combination approaches
  • Determine the role of specialty and managed care pharmacists in the interprofessional collaborative care team to support evidence-based, equitable care that improves patient outcomes

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-013-L01-P has been assigned to this live application-based activity (initial release date 4/30/2023). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

Supported by educational grants from AstraZeneca and BeiGene.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191